Hexima Limited

Equities

HXL

AU0000111932

Biotechnology & Medical Research

Market Closed - Australian S.E. 12:44:41 2024-03-25 am EDT 5-day change 1st Jan Change
0.012 AUD -7.69% Intraday chart for Hexima Limited -7.69% -33.33%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Hexima Secures R&D Tax Rebate for Fiscal Year 2023 MT
Hexima Changes Address MT
Hexima Limited Announces Change of Address CI
Hexima Limited Reports Earnings Results for the Half Year Ended December 31, 2023 CI
Hexima Limited Announces the Resignation of Dr. Nicole Van Der Weerden as Director CI
Hexima Limited Appoints Phillip Hains as A Non-Executive Director CI
Hexima Limited Appoints Geoffrey Kempler as Managing Director CI
Hexima Limited Announces Executive Changes CI
Hexima Limited Reports Earnings Results for the Full Year Ended June 30, 2023 CI
Hexima Limited Announces Resignation of Mr. Steven Skala as an Alternate Director CI
Hexima Limited Reports Earnings Results for the Half Year Ended December 31, 2022 CI
Hexima Limited Declares Voting Results CI
Arovella Therapeutics Appoints COO MT
Hexima Acting CEO to Step Down MT
Nicole Van Der Weerden to Step Down as CEO of Hexima Limited CI
Hexima Receives AU$6 Million Tax Incentive Refund from Australian Taxation Office MT
Hexima Limited Receives Requisition Notice from Merchant Biotech Fund CI
Hexima Limited Announces Board Changes CI
10,150,000 Options of Hexima Limited are subject to a Lock-Up Agreement Ending on 1-DEC-2022. CI
6,925,878 Ordinary Shares of Hexima Limited are subject to a Lock-Up Agreement Ending on 1-DEC-2022. CI
Hexima Limited Announces Change of Address CI
Hexima Limited Reports Earnings Results for the Full Year Ended June 30, 2022 CI
Hexima Managing Director, CEO Steps Down MT
Hexima Limited Announces Management Changes CI
Hexima Limited Announces Phase II Results of Pezadeftide CI
Chart Hexima Limited
More charts
Hexima Limited is an Australia-based clinical-stage, anti-infectives focused biotechnology company. The Company is engaged in the research and development of plant defensin peptides for applications in human therapeutics. Its lead drug candidate is the plant defensin, pezadeftide, developed for the treatment of fungal nail infections. The Company is conducting phase II clinical trial testing pezadeftide as a treatment for onychomycosis. Its Antifungal Plant Defensin Technology platform is engaged in identifying several plant peptides with potent antifungal activity against a broad range of human fungal pathogens. It is also investigating the application of its plant defensin technology to other human fungal diseases.
More about the company

Annual profits - Rate of surprise